Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALG-097558 Phase 1 Safety, PK, and DDI Study
NCT05840952Phase 1Completed
- Sponsor
- Aligos Therapeutics
- Start
- Jul 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALG-097558 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Aligos Therapeutics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 28 days, Area under the concentration time curve up to 19 days and 5 more. Started Jul 2023; status: completed.
02
Drugs
ALG-097558
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05840952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05840952.